Treatment Goals for Achondroplasia: A Qualitative Study with Parents and Adults

Dr. Sarah A. McGraw, Co-Founder, Partner at MNW Consulting Group

THG partnered with MNW Consulting Group’s Sarah McGraw to publish a research paper on Achondroplasia titled “Advances in Therapy”.

 

Achondroplasia is the most common cause of disproportionate short stature and can be associated with medical complications. Pharmacologic treatments are becoming available. We conducted a qualitative study to examine the treatment goals of parents of children with achondroplasia and adults with the condition. Participants in this study hoped that treatment would both ameliorate medical complications and increase stature. For some, treatment would help with functional limitations and social challenges. 

 

 

 

 

ABSTRACT

 

Introduction:

 

Achondroplasia is characterized by disproportionate short stature accompanied by other changes to the musculoskeletal system. Individuals with this condition typically experience a variety of medical complications. As pharmacologic treatments continue to be developed for the treatment of achondroplasia, it is important to understand treatment goals among those affected by achondroplasia and the factors that shape their goals.

 

Methods:

 

This qualitative study is based on semi-structured interviews with 19 parents of children with achondroplasia and five adults with achondroplasia in the USA. We employed thematic analysis using an iterative process to identify themes across the interviews.

 

Results:

 

Participants had two goals for pharmacologic treatment of achondroplasia: ameliorating complications associated with the condition and increasing stature to overcome functional limitations and psychosocial challenges. Complications of particular concern were chronic pain and surgeries to repair spinal, ear, nose, and throat (ENT) problems, and neurological sequelae. Increased height would enhance independence, help individuals to fit in socially, and avoid social stigma. Countervailing factors included the importance of stature to their identity and the concern that the condition would remain despite treatment.

 

Conclusions:

 

This study offers evidence about how individuals affected by achondroplasia think about the pharmacologic treatment of this condition, including both the benefits of ameliorating complications and increasing height. The findings can offer practical insights for parents of children considering treatment, treating physicians, and decision-makers evaluating coverage decisions for treatment of achondroplasia.

Stay connected - Subscribe to our quarterly newsletter

* indicates required

Related Articles

Print | Sitemap
© The Henne Group - IONOS MyWebsite